Viaderma Inc. (VDRM) 0.0037 $VDRM
ViaDerma, Inc., to Initiate Upcoming Field Trial of Comparison for Onychomycosis
GlobeNewswire - Mon Mar 02, 8:17AM CST
ViaDerma, Inc. (OTCQB:VDRM) (The Company), a specialty pharmaceutical company devoted to bringing new products to market, is excited to start participating in test trials with a major Food and Drug Administration (FDA) approved toenail fungus treatment.
ViaDerma, Inc. Announces Preston Richards to Join Advisory Board
GlobeNewswire - Thu Jan 22, 9:03AM CST
ViaDerma, Inc. (OTC:VDRM), a developer of advanced topical pharmaceuticals, is pleased to announce the addition of Preston Richards to their Advisory Board.
ViaDerma, Inc. Launches New Website
GlobeNewswire - Tue Jan 13, 8:01AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to the market, is excited to officially announce its new website viadermalicensing.com. The new site features extensive company information that has been carefully revamped in preparation for increased marketing, sales and distribution efforts which will be a focus in 2015.
TetraStem(TM) Antibiotic Continues to Demonstrate Treatment Success Leading Management to Explore Partnerships With Big Pharmaceutical Companies
GlobeNewswire - Tue Dec 09, 8:44AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced TetraStem, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.'
ViaDerma, Inc. Lead Product TetraStem Shows Promise in Treating Acne
GlobeNewswire - Fri Nov 21, 9:16AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery method to apply almost any active ingredient to a topical drug. It has recently shown promising results for acne sufferers with the minimal side effects that are usually associated with other medications.
ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board
GlobeNewswire - Thu Nov 13, 10:26AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is pleased to announce the appointment of Dr. Andrew Berman as the Medical Director of the advisory board.
TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations
GlobeNewswire - Fri Nov 07, 7:54AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.
These Small-Cap Marijuana Stocks are in Play Next Week
ACCESSWIRE - Fri Oct 31, 11:35AM CDT
Coral Gables, FL / ACCESSWIRE / October 31, 2014 / ViaDerma, Inc. (OTCQB: VDRM) ecently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA
PR Newswire - Thu Oct 30, 7:00AM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015
PR Newswire - Wed Oct 29, 2:26PM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is committed to pursuing out-licensing partnerships in 2015.
ViaDerma, Inc. Announces Strategic Partnership With The Brewer Group
PR Newswire - Tue Aug 05, 8:36AM CDT
ViaDerma, Inc. (OTCQB: VDRM), a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development, and The Brewer Group, Inc. (TBG), a diversified global investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma's business development and marketing efforts at home and abroad to grow interest in ViaDerma's patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of active ingredients and immediate relief of symptoms.
ViaDerma, Inc., to Initiate Upcoming Field Trial of Comparison for Onychomycosis
GlobeNewswire - Mon Mar 02, 8:17AM CST
ViaDerma, Inc. (OTCQB:VDRM) (The Company), a specialty pharmaceutical company devoted to bringing new products to market, is excited to start participating in test trials with a major Food and Drug Administration (FDA) approved toenail fungus treatment.
ViaDerma, Inc. Announces Preston Richards to Join Advisory Board
GlobeNewswire - Thu Jan 22, 9:03AM CST
ViaDerma, Inc. (OTC:VDRM), a developer of advanced topical pharmaceuticals, is pleased to announce the addition of Preston Richards to their Advisory Board.
ViaDerma, Inc. Launches New Website
GlobeNewswire - Tue Jan 13, 8:01AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to the market, is excited to officially announce its new website viadermalicensing.com. The new site features extensive company information that has been carefully revamped in preparation for increased marketing, sales and distribution efforts which will be a focus in 2015.
TetraStem(TM) Antibiotic Continues to Demonstrate Treatment Success Leading Management to Explore Partnerships With Big Pharmaceutical Companies
GlobeNewswire - Tue Dec 09, 8:44AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced TetraStem, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.'
ViaDerma, Inc. Lead Product TetraStem Shows Promise in Treating Acne
GlobeNewswire - Fri Nov 21, 9:16AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery method to apply almost any active ingredient to a topical drug. It has recently shown promising results for acne sufferers with the minimal side effects that are usually associated with other medications.
ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board
GlobeNewswire - Thu Nov 13, 10:26AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is pleased to announce the appointment of Dr. Andrew Berman as the Medical Director of the advisory board.
TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations
GlobeNewswire - Fri Nov 07, 7:54AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.
These Small-Cap Marijuana Stocks are in Play Next Week
ACCESSWIRE - Fri Oct 31, 11:35AM CDT
Coral Gables, FL / ACCESSWIRE / October 31, 2014 / ViaDerma, Inc. (OTCQB: VDRM) ecently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA
PR Newswire - Thu Oct 30, 7:00AM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015
PR Newswire - Wed Oct 29, 2:26PM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is committed to pursuing out-licensing partnerships in 2015.
ViaDerma, Inc. Announces Strategic Partnership With The Brewer Group
PR Newswire - Tue Aug 05, 8:36AM CDT
ViaDerma, Inc. (OTCQB: VDRM), a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development, and The Brewer Group, Inc. (TBG), a diversified global investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma's business development and marketing efforts at home and abroad to grow interest in ViaDerma's patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of active ingredients and immediate relief of symptoms.
